Efficacy and tolerability of ustekinumab in patients with ulcerative colitis after failure of first-line therapy with genetically engineered biological agents
- 作者: Iakovlev A.A.1, Volkov A.S.1, Bashtovaya O.A.1
-
隶属关系:
- Rostov State Medical University of the Ministry of Healthcare of Russia
- 期: 卷 11, 编号 5 (2025)
- 页面: 112-117
- 栏目: CLINICAL CASES
- URL: https://journals.eco-vector.com/2412-4036/article/view/689028
- DOI: https://doi.org/10.18565/therapy.2025.5.112-117
- ID: 689028
如何引用文章
详细
Article describes a clinical observation of a 49-year-old female patient with 25-year history of severe steroid-dependent ulcerative colitis (UC). The patient had ineffective/intolerant treatment with 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and budesonide MMX. Remission was achieved with etrolizumab (4.5 years), but a relapse occurred after its discontinuation. During an exacerbation of UC (April 2023, Mayo 3), ustekinumab was prescribed: induction – 6 mg per kilogram intravenously, maintenance therapy – 90 mg subcutaneously every 12 weeks. As a result, it was possible to achieve stable clinical remission lasting 2 years. Endoscopy (April 2025) showed minimal UC activity (Mayo 1), histological examination – disease activity of 2 points according to Riley with the signs of healing. Thus, ustekinumab effectively induced and maintained remission in a female patient with UC refractory to the therapy by genetically engineered biological medicinal product of the first line.
全文:

作者简介
Alexey Iakovlev
Rostov State Medical University of the Ministry of Healthcare of Russia
编辑信件的主要联系方式.
Email: gastroklinika@yandex.ru
ORCID iD: 0000-0003-1697-8989
SPIN 代码: 4699-2807
MD, Dr. Sci. (Medicine), professor, head of the Department of gastroenterology and endoscopy
俄罗斯联邦, Rostov-on-DonAlexander Volkov
Rostov State Medical University of the Ministry of Healthcare of Russia
Email: medicina_volkov@mail.ru
ORCID iD: 0009-0000-3227-1225
SPIN 代码: 1718-1989
MD, PhD (Medicine), associate professor of the Department of gastroenterology and endoscopy
俄罗斯联邦, Rostov-on-DonOlga Bashtovaya
Rostov State Medical University of the Ministry of Healthcare of Russia
Email: gastro_olga@mail.ru
ORCID iD: 0000-0003-1629-2936
SPIN 代码: 3829-7735
MD, gastroenterologist at the Department of therapy No. 1 Clinic
俄罗斯联邦, Rostov-on-Don参考
- Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А., Решетов И.В., Маев И.В., Ачкасов С.И. с соавт. Язвенный колит (К.51), взрослые. Колопроктология. 2023;22(1):10–44. [Shelygin YuA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI et al. Ulcerative colitis (K.51), adults. Koloproktologiya = Coloproctology. 2023;22(1):10–44 (In Russ.)]. EDN: GDYCMT. https://doi.org/0.33878/2073-7556-2023-22-1-10-44
- Князев О.В., Шкурко Т.В., Фадеева Н.А., Бакулин И.Г., Бордин Д.С. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра. Экспериментальная и клиническая гастроэнтерология. 2017;(3):4–12. [Knyazev OV, Shkurko TV, Fadeeva NA, Bakulin IG, Bordin DS. Epidemiology of chronic inflammatory disease. Yesterday, today, tomorrow. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2017;(3):4–12 (In Russ.)]. EDN: ZRPJFX.
- Водовозов А. Современный подход к терапии язвенного колита: обновленные рекомендации Американской гастроэнтерологической ассоциации. Ремедиум. 2021;(2):62–68. [Vodovozov A. Modern approach to the treatment of ulcerative colitis: Updated recommendations of the American Gastroenterological Association. Remedium. 2021;(2):62–68 (In Russ.)]. EDN: SLRGAN. https://doi.org/10.21518/1561-5936-2021-2-62-68
- Kochhar GS, Desai A, Farraye FA, Cross RK, El-Hachem S, Dulai PS, Regueiro M. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study. Aliment Pharmacol Ther. 2023;58(3):297–308. PMID: 37300328. https://doi.org/10.1111/apt.17570
- Bhattacharya A, Osterman MT. Biologic therapy for ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):717–29. PMID: 33121691. https://doi.org/10.1016/j.gtc.2020.08.002
- Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70. PMID: 34856198. https://doi.org/10.1016/S2468-1253(21)00377-0
- Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A et al. Effectiveness of ustekinumab for patients with moderate-to-severe ulcerative colitis: A multicenter real-world Canadian Study. Am J Gastroenterol. 2024. PMID: 39657015. https://doi.org/10.14309/ajg.0000000000003212
- Burbage S, Knight H, Godwin B, Meadows R, Jones W, Zhao R, Kachroo S. The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States. Curr Med Res Opin. 2025;41(4):683–89. PMID: 40327500. https://doi.org/10.1080/03007995.2025.2494642
- Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR et al.; HIBISCUS Study Group. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): Two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17–27. PMID: 34798036. https://doi.org/10.1016/S2468-1253(21)00338-1
- Motawea KR, Abdelghafar YA, AbdelQadir YH, Aboelenein MM, Ibrahim N, Belal MM et al. Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis. Health Sci Rep. 2024;7(5):e882. PMID: 38736478. PMCID: PMC11082092. https://doi.org/10.1002/hsr2.882
- Taxonera C, Olivares D, López-García O.N, Alba C. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–19. PMID: 36645145. https://doi.org/10.1111/apt.17386
补充文件
